Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 2INTERVENTIONAL

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

Evaluation of Ultralow Dose PET Imaging for Detecting Amyloid Tracer Uptake

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age ≥18 years. 2. Ability to provide willing to sign a consent form and comply with study procedures. 3. For female participants: - Must not be pregnant or breastfeeding. - Negative pregnancy test required for women of childbearing potential. Who Should NOT Join This Trial: 1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total). 2. More than four prior enrollments in this study. 3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan 4. Pregnant or breastfeeding individuals (negative pregnancy test required) 5. Inability to provide willing to sign a consent form 6. Any condition that, in the investigator's judgment, may compromise participant safety or study integrity. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Age ≥18 years. 2. Ability to provide informed consent and comply with study procedures. 3. For female participants: * Must not be pregnant or breastfeeding. * Negative pregnancy test required for women of childbearing potential. Exclusion Criteria: 1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total). 2. More than four prior enrollments in this study. 3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan 4. Pregnant or breastfeeding individuals (negative pregnancy test required) 5. Inability to provide informed consent 6. Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.

Treatments Being Tested

DRUG

18F-Florbetapir or 18F-Flutemetamol

Participants will be injected with 18F-Florbetapir or 18F-Flutemetamol and imaged for up to 3 hours on a PET scanner

Locations (1)

Nuclear Imaging Institute
Englewood, New Jersey, United States